The research that matters, without the jargon.

Thyroid hormone receptor-β agonist simedeutirom (HSK31679) for Chinese patients with metabolic dysfunction-associated steatohepatitis: a 52-week, multicentre, randomised, double-blind, placebo-controlled, phase 2b trial

Simedeutirom led to higher rates of MASH improvement without worsening of fibrosis (tissue scarring) than placebo (inactive comparison treatment) after 52 weeks, warranting further investigation in Phase 3 trials. Simedeutirom is a selective thyroid hormone receptor-β agonist that has previously been shown to reduce hepatic fat content in metabolic dysfunction-associated steatotic liver disease.